Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
71 hedge funds and large institutions have $18.8M invested in Surface Oncology, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 26 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more call options, than puts
Call options by funds: $2K | Put options by funds: $2K
9% less funds holding
Funds holding: 78 → 71 (-7)
19% less capital invested
Capital invested by funds: $23.2M → $18.8M (-$4.48M)
31% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 26
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$705K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$257K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$40.5K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$22.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$682K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$399K |
| 3 |
Goldman Sachs
New York
|
-$365K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$118K |
| 5 |
KOCAA
Knights of Columbus Asset Advisors
New Haven,
Connecticut
|
-$101K |
SURF Hedge Fund Activity: Q1 2023 in Review
71 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q1 2023, worth a combined $18.8M — down 19% from $23.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SURF and 3 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 18 added.
The largest buyer was Tang Capital Management, adding an estimated $705K. The largest seller was EcoR1 Capital, cutting an estimated $682K.
- 71 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q1 2023, down from 78 in Q4 2022.
- Funds reported $18.8M of Surface Oncology, Inc. Common Stock stock for Q1 2023, down 19% quarter-over-quarter.
- 3 funds opened new Surface Oncology, Inc. Common Stock positions in Q1 2023 and 9 closed out, a net change of -6 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q1 2023 was Tang Capital Management, an estimated $705K added.
- The largest Surface Oncology, Inc. Common Stock seller in Q1 2023 was EcoR1 Capital, an estimated $682K sold.
Based on aggregated 13F filings for Q1 2023.